Hepatocellular carcinoma (HCC) and advanced colorectal cancer (CRC) are among the most deadly diseases of mankind. CRC is the second leading cause of cancer-related death in the United States, mostly due to metastases. Hepatic metastases are the main threat for successful treatment of CRC. 5-fluorouracil (5-FU). remains the mainstay of combination chemotherapy for nonresectable liver metastases. Recent studies have demonstrated that regional 5-FU-based chemotherapy by directly hepatic fusion showed improved response rates and survival for advanced CRC patients as compared with those undergone systemic infusion treatment. However, this delivery system is technically complicated and highly invasive. The present application describes the development of a novel delivery system for the treatment of hepatic metastases of CRC. The approach involves the use of a recombinant fusion protein consisting of malarial circumsporozoite (CS) protein, a hepatocyte-specific targeting ligand, linked to bacterial cytosine deaminase (CD), a """"""""suicide gene"""""""" product which catalyzes the synthesis of 5-fluorouracil (5-FU) from its prodrug 5-fluorocytosine (5-FC). We have demonstrated in cultured cells that the CD-CS fusion protein can be internalized by a cell type-specific manner. More importantly, the internalized recombinant protein is stable for at least four weeks and exerts bystander cell killing effects upon the administration of prodrug 5-FC. The prolonged stability is probably attributed to the mechanism that the internalized fusion recombinant protein is entrapped in particular compartment(s) that are free from cytoplasmic degradation machinery. To further develop this system, we propose the following three specific aims: (A) to elucidate the mechanism(s) underlying the prolonged stability of CD-CS in cultured cells; (B) to investigate the targeting specificity, protein stability, and enzymatic activity of CD-CS in normal mice; and (C) to investigate the efficacy of CDCS/5-FC strategy in the treatment of liver metastases of colorectal cancers in animal model. We envision that the novel hepatic prodrug targeted therapy strategy proposed here, if successfully, is technically simple and non-invasive, and cost effective, therefore, should greatly improve the treatment efficacy of these life threatening diseases.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Research Project (R01)
Project #
1R01CA095003-01
Application #
6458230
Study Section
Experimental Therapeutics Subcommittee 1 (ET)
Program Officer
Forry, Suzanne L
Project Start
2002-09-01
Project End
2006-08-31
Budget Start
2002-09-01
Budget End
2003-08-31
Support Year
1
Fiscal Year
2002
Total Cost
$268,780
Indirect Cost
Name
University of Texas MD Anderson Cancer Center
Department
Pathology
Type
Other Domestic Higher Education
DUNS #
001910777
City
Houston
State
TX
Country
United States
Zip Code
77030
Kang, Sohee; Savas, Sevtap; Ozcelik, Hilmi et al. (2014) Inferring gene network from candidate SNP association studies using a Bayesian graphical model: application to a breast cancer case-control study from ontario. Hum Hered 78:140-52
Morley, Katherine I; Milne, Roger L; Giles, Graham G et al. (2010) Socio-economic status and survival from breast cancer for young, Australian, urban women. Aust N Z J Public Health 34:200-5
Gaudet, Mia M; Milne, Roger L; Cox, Angela et al. (2009) Five polymorphisms and breast cancer risk: results from the Breast Cancer Association Consortium. Cancer Epidemiol Biomarkers Prev 18:1610-6
Johnatty, Sharon E; Beesley, Jonathan; Chen, Xiaoqing et al. (2009) The BARD1 Cys557Ser polymorphism and breast cancer risk: an Australian case-control and family analysis. Breast Cancer Res Treat 115:145-50
Kurian, Allison W; Gong, Gail D; John, Esther M et al. (2009) Performance of prediction models for BRCA mutation carriage in three racial/ethnic groups: findings from the Northern California Breast Cancer Family Registry. Cancer Epidemiol Biomarkers Prev 18:1084-91
Breast Cancer Family Registry; Kathleen Cuningham Consortium for Research into Familial Breast Cancer (Australasia); Ontario Cancer Genetics Network (Canada) (2008) Smoking and risk of breast cancer in carriers of mutations in BRCA1 or BRCA2 aged less than 50 years. Breast Cancer Res Treat 109:67-75
Hammet, Fleur; George, Jessica; Tesoriero, Andrea A et al. (2008) Is BRCA2 c.9079 G>A a predisposing variant for early onset breast cancer? Breast Cancer Res Treat 109:177-9
Song, Im-Sook; Chen, Helen H W; Aiba, Isamu et al. (2008) Transcription factor Sp1 plays an important role in the regulation of copper homeostasis in mammalian cells. Mol Pharmacol 74:705-13
Frank, Bernd; Wiestler, Miriam; Kropp, Silke et al. (2008) Association of a common AKAP9 variant with breast cancer risk: a collaborative analysis. J Natl Cancer Inst 100:437-42
Wong, Ee Ming; Tesoriero, Andrea A; Pupo, Gulietta M et al. (2008) Is MSH2 a breast cancer susceptibility gene? Fam Cancer 7:151-5

Showing the most recent 10 out of 54 publications